Cabaletta BioCABA -0.48%34 PB Ratio is 3.35 as of Jul. 01, 2026. GuruFocus rates CABA with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,229 Biotechnology companies, Cabaletta Bio ranks worse than 56.06% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-01), Cabaletta Bio's share price is $3.11. Cabaletta Bio's Book Value per Share for the quarter that ended in Mar. 2026 was $0.93. Hence, Cabaletta Bio's PB Ratio of today is 3.35.
The historical rank and industry rank for Cabaletta Bio's PB Ratio or its related term are showing as below:
CABA'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 3.35
Current: 3.35
During the past 9 years, Cabaletta Bio's highest PB Ratio was 3.35. The lowest was 0.00. And the median was 0.00.
CABA's PB Ratio is ranked worse than 56.06% of 1229
companies
in the Biotechnology industry
Industry Median: 2.87
vs CABA: 3.35
During the past 12 months, Cabaletta Bio's average Book Value Per Share Growth Rate was -62.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -32.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -19.50% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Cabaletta Bio was 3.80% per year. The lowest was -32.00% per year. And the median was -12.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cabaletta Bio PB Ratio Related Terms
Cabaletta Bio PB Ratio Historical Data
* Premium members only.
The historical data trend for Cabaletta Bio's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cabaletta Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cabaletta Bio PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cabaletta Bio's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cabaletta Bio's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Cabaletta Bio's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cabaletta Bio (CABA) has a PB Ratio of 3.35 as of Jul. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cabaletta Bio and its competitors. According to the industry distribution chart, Cabaletta Bio ranks #689 out of 1229 companies in the Biotechnology industry, placing it in the top 56.1%.
Is Cabaletta Bio's PB Ratio too high?
Cabaletta Bio's current PB Ratio is 3.35. The Biotechnology industry median PB Ratio is 2.87. Cabaletta Bio's value of 3.35 is 16.7% above this industry median. Based on the distribution chart, Cabaletta Bio ranks #689 out of 1229 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cabaletta Bio has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cabaletta Bio's PB Ratio compare to RZLT and CCCC?
According to the Biotechnology industry distribution chart, Cabaletta Bio ranks #689 out of 1229 companies for PB Ratio. This places Cabaletta Bio in the lower half of its industry. The industry median PB Ratio is 2.87. Cabaletta Bio's value of 3.35 is 16.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.87, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cabaletta Bio's current PB Ratio of 3.35 is 16.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cabaletta Bio and its competitors. For the Biotechnology industry, the median PB Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cabaletta Bio's current PB Ratio is 3.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cabaletta Bio stock overvalued right now?
Cabaletta Bio (CABA) has a current PB Ratio of 3.35. The current PB Ratio is 3.35 and 16.7% above the Biotechnology industry median of 2.87. Cabaletta Bio's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cabaletta Bio (CABA), the current PB Ratio is 3.35 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
34GF Score
Get the complete analysis for CABA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CABA has been successfully added to your 
